Women Face 1.5-to-2 Times Higher Drug-Reaction Risk From Unregulated Peptides
Updated
Updated · The Conversation · Jul 1
Women Face 1.5-to-2 Times Higher Drug-Reaction Risk From Unregulated Peptides
2 articles · Updated · The Conversation · Jul 1
Summary
Women appear markedly more vulnerable to unregulated peptides, with evidence showing they are 1.5 to 2 times more likely than men to suffer adverse drug reactions.
That gap is driven by heavier medication use, more chronic conditions and sex-based differences in drug metabolism, hormones and immune response, which can amplify interactions and side effects.
Ipamorelin and CJC-1295, sold for muscle growth and anti-ageing, can keep growth hormone and IGF-1 elevated for days, a pattern linked to fluid retention, ovarian disruption and higher miscarriage risk.
TB-500 and injectable GHK-Cu raise separate concerns: thymosin beta-4 has been found in breast and lung cancer cells, while excess copper in pregnancy has been tied to a 30% higher prematurity risk per additional microgram per millilitre.
Injection adds another layer of uncertainty because these products are unlicensed, vial strength is often unclear, and women’s lower body water and different fat distribution can make the same dose hit harder.